Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Adrenocorticotropic Hormone for Childhood Nephrotic Syndrome: The ATLANTIS Randomized Trial.

Wang CS, Travers C, McCracken C, Leong T, Gbadegesin R, Quiroga A, Benfield MR, Hidalgo G, Srivastava T, Lo M, Yadin O, Mathias R, Araya CE, Khalid M, Orjuela A, Zaritsky J, Al-Akash S, Kamel M, Greenbaum LA.

Clin J Am Soc Nephrol. 2018 Dec 7;13(12):1859-1865. doi: 10.2215/CJN.06890618. Epub 2018 Nov 15.

PMID:
30442868
2.

Poor adherence to early childhood blood pressure measurement guidelines in a large pediatric healthcare system.

Shah L, Hossain J, Xie S, Zaritsky J.

Pediatr Nephrol. 2018 Nov 7. doi: 10.1007/s00467-018-4132-y. [Epub ahead of print]

PMID:
30406366
3.

Pharmacokinetics of ferric pyrophosphate citrate administered via dialysate and intravenously to pediatric patients on chronic hemodialysis.

Pratt RD, Grimberg S, Zaritsky JJ, Warady BA.

Pediatr Nephrol. 2018 Jul 12. doi: 10.1007/s00467-018-4014-3. [Epub ahead of print]

4.

Ambulatory hypertension in a pediatric cohort of sickle cell disease.

Moodalbail DG, Falkner B, Keith SW, Mathias RS, Araya CE, Zaritsky JJ, Stuart MJ.

J Am Soc Hypertens. 2018 Jul;12(7):542-550. doi: 10.1016/j.jash.2018.04.005. Epub 2018 May 5.

PMID:
29804939
5.

Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.

Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE.

Nat Rev Nephrol. 2017 Dec 13;14(1):70. doi: 10.1038/nrneph.2017.175.

PMID:
29234164
6.

Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.

Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE.

Nat Rev Nephrol. 2018 Jan;14(1):57-70. doi: 10.1038/nrneph.2017.155. Epub 2017 Nov 27. Review. Erratum in: Nat Rev Nephrol. 2017 Dec 13;14 (1):70.

7.

Epidemiology of peritonitis following maintenance peritoneal dialysis catheter placement during infancy: a report of the SCOPE collaborative.

Zaritsky JJ, Hanevold C, Quigley R, Richardson T, Wong C, Ehrlich J, Lawlor J, Rodean J, Neu A, Warady BA; SCOPE Investigators.

Pediatr Nephrol. 2018 Apr;33(4):713-722. doi: 10.1007/s00467-017-3839-5. Epub 2017 Nov 17.

PMID:
29150711
8.

A case of Fanconi syndrome due to a deferasirox overdose and a trial of plasmapheresis.

Shah L, Powell JL, Zaritsky JJ.

J Clin Pharm Ther. 2017 Oct;42(5):634-637. doi: 10.1111/jcpt.12553. Epub 2017 May 29.

PMID:
28556939
9.

Increased serum hepcidin contributes to the anemia of chronic kidney disease in a murine model.

Hanudel MR, Rappaport M, Gabayan V, Jung G, Salusky IB, Nemeth E, Ganz T, Zaritsky J.

Haematologica. 2017 Mar;102(3):e85-e88. doi: 10.3324/haematol.2016.150433. Epub 2016 Nov 24. No abstract available.

10.

Contrast-enhanced magnetic resonance venography in pediatric patients with chronic kidney disease: initial experience with ferumoxytol.

Luhar A, Khan S, Finn JP, Ghahremani S, Griggs R, Zaritsky J, Salusky I, Hall TR.

Pediatr Radiol. 2016 Aug;46(9):1332-40. doi: 10.1007/s00247-016-3605-z. Epub 2016 Apr 8. Review.

PMID:
27059620
11.

Recessive nephrocerebellar syndrome on the Galloway-Mowat syndrome spectrum is caused by homozygous protein-truncating mutations of WDR73.

Jinks RN, Puffenberger EG, Baple E, Harding B, Crino P, Fogo AB, Wenger O, Xin B, Koehler AE, McGlincy MH, Provencher MM, Smith JD, Tran L, Al Turki S, Chioza BA, Cross H, Harlalka GV, Hurles ME, Maroofian R, Heaps AD, Morton MC, Stempak L, Hildebrandt F, Sadowski CE, Zaritsky J, Campellone K, Morton DH, Wang H, Crosby A, Strauss KA.

Brain. 2015 Aug;138(Pt 8):2173-90. doi: 10.1093/brain/awv153. Epub 2015 Jun 11.

12.

The use of renal replacement therapy in critically ill pediatric small bowel transplantation candidates and recipients: Experience from one center.

Pineda C, Grogan T, Lin JA, Zaritsky JJ, Venick R, Farmer DG, Kelly RB.

Pediatr Transplant. 2015 Jun;19(4):E88-92. doi: 10.1111/petr.12456. Epub 2015 Mar 26.

13.

Antibacterial responses by peritoneal macrophages are enhanced following vitamin D supplementation.

Bacchetta J, Chun RF, Gales B, Zaritsky JJ, Leroy S, Wesseling-Perry K, Boregaard N, Rastogi A, Salusky IB, Hewison M.

PLoS One. 2014 Dec 30;9(12):e116530. doi: 10.1371/journal.pone.0116530. eCollection 2014.

14.

High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohort.

Nayak AB, Luhar A, Hanudel M, Gales B, Hall TR, Finn JP, Salusky IB, Zaritsky J.

Pediatr Nephrol. 2015 Mar;30(3):515-21. doi: 10.1007/s00467-014-2953-x. Epub 2014 Sep 12.

15.

Chronic kidney disease in the neonate.

Zaritsky JJ, Warady BA.

Clin Perinatol. 2014 Sep;41(3):503-15. doi: 10.1016/j.clp.2014.05.002. Epub 2014 Jul 25. Review.

PMID:
25155723
16.

The accuracy of a continuous volumetric balancing system in pediatric continuous renal replacement therapy.

Hanudel MR, Salusky IB, Zaritsky JJ.

Int J Artif Organs. 2014 Mar;37(3):215-21. doi: 10.5301/ijao.5000296. Epub 2014 Apr 4.

17.

Suppression of iron-regulatory hepcidin by vitamin D.

Bacchetta J, Zaritsky JJ, Sea JL, Chun RF, Lisse TS, Zavala K, Nayak A, Wesseling-Perry K, Westerman M, Hollis BW, Salusky IB, Hewison M.

J Am Soc Nephrol. 2014 Mar;25(3):564-72. doi: 10.1681/ASN.2013040355. Epub 2013 Nov 7.

18.

A biphasic dialytic strategy for the treatment of neonatal hyperammonemia.

Hanudel M, Avasare S, Tsai E, Yadin O, Zaritsky J.

Pediatr Nephrol. 2014 Feb;29(2):315-20.

19.

Short daily hemodialysis is associated with lower plasma FGF23 levels when compared with conventional hemodialysis.

Zaritsky J, Rastogi A, Fischmann G, Yan J, Kleinman K, Chow G, Gales B, Salusky IB, Wesseling-Perry K.

Nephrol Dial Transplant. 2014 Feb;29(2):437-41. doi: 10.1093/ndt/gft382. Epub 2013 Sep 5.

20.

Correlates of parathyroid hormone concentration in hemodialysis patients.

Li J, Molnar MZ, Zaritsky JJ, Sim JJ, Streja E, Kovesdy CP, Salusky I, Kalantar-Zadeh K.

Nephrol Dial Transplant. 2013 Jun;28(6):1516-25. doi: 10.1093/ndt/gfs598. Epub 2013 Jan 24.

21.

Risk factors for morbidity and mortality in pediatric patients with peritoneal dialysis catheters.

Phan J, Stanford S, Zaritsky JJ, DeUgarte DA.

J Pediatr Surg. 2013 Jan;48(1):197-202. doi: 10.1016/j.jpedsurg.2012.10.035.

PMID:
23331815
22.

Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients.

Rattanasompattikul M, Molnar MZ, Zaritsky JJ, Hatamizadeh P, Jing J, Norris KC, Kovesdy CP, Kalantar-Zadeh K.

Nephrol Dial Transplant. 2013 Jul;28(7):1936-45. doi: 10.1093/ndt/gfs368. Epub 2012 Oct 8.

23.

Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis.

Miller JE, Molnar MZ, Kovesdy CP, Zaritsky JJ, Streja E, Salusky I, Arah OA, Kalantar-Zadeh K.

Pharmacoepidemiol Drug Saf. 2012 Nov;21(11):1232-9. doi: 10.1002/pds.3349. Epub 2012 Sep 20.

24.

Ventriculoperitoneal shunts in children on peritoneal dialysis: a survey of the International Pediatric Peritoneal Dialysis Network.

Dolan NM, Borzych-Duzalka D, Suarez A, Principi I, Hernandez O, Al-Akash S, Alconchar L, Breen C, Fischbach M, Flynn J, Pape L, Piantanida JJ, Printza N, Wong W, Zaritsky J, Schaefer F, Warady BA, White CT.

Pediatr Nephrol. 2013 Feb;28(2):315-9. doi: 10.1007/s00467-012-2303-9. Epub 2012 Sep 14.

PMID:
22972407
25.

Hemoglobin level and survival in hemodialysis patients with polycystic kidney disease and the role of administered erythropoietin.

Shah A, Molnar MZ, Lukowsky LR, Zaritsky JJ, Kovesdy CP, Kalantar-Zadeh K.

Am J Hematol. 2012 Aug;87(8):833-6. doi: 10.1002/ajh.23255. Epub 2012 May 28.

26.

Mortality associated with dose response of erythropoiesis-stimulating agents in hemodialysis versus peritoneal dialysis patients.

Duong U, Kalantar-Zadeh K, Molnar MZ, Zaritsky JJ, Teitelbaum I, Kovesdy CP, Mehrotra R.

Am J Nephrol. 2012;35(2):198-208. doi: 10.1159/000335685. Epub 2012 Jan 26.

27.

The crossroad of RAAS modulation, inflammation, and oxidative stress in dialysis patients: light at the end of the tunnel?

Zaritsky JJ, Kalantar-Zadeh K.

J Am Soc Nephrol. 2012 Feb;23(2):189-91. doi: 10.1681/ASN.2011121208. Epub 2012 Jan 12. No abstract available.

28.

Mineral and bone disorders and survival in hemodialysis patients with and without polycystic kidney disease.

Lukowsky LR, Molnar MZ, Zaritsky JJ, Sim JJ, Mucsi I, Kovesdy CP, Kalantar-Zadeh K.

Nephrol Dial Transplant. 2012 Jul;27(7):2899-907. doi: 10.1093/ndt/gfr747. Epub 2011 Dec 29.

29.

Early skeletal and biochemical alterations in pediatric chronic kidney disease.

Wesseling-Perry K, Pereira RC, Tseng CH, Elashoff R, Zaritsky JJ, Yadin O, Sahney S, Gales B, J├╝ppner H, Salusky IB.

Clin J Am Soc Nephrol. 2012 Jan;7(1):146-52. doi: 10.2215/CJN.05940611. Epub 2011 Nov 3.

30.

Defining left ventricular hypertrophy in children on peritoneal dialysis.

Borzych D, Bakkaloglu SA, Zaritsky J, Suarez A, Wong W, Ranchin B, Qi C, Szabo AJ, Coccia PA, Harambat J, Mitu F, Warady BA, Schaefer F; International Pediatric Peritoneal Dialysis Network.

Clin J Am Soc Nephrol. 2011 Aug;6(8):1934-43. doi: 10.2215/CJN.11411210. Epub 2011 Jul 7.

31.

Peritoneal dialysis in infants and young children.

Zaritsky J, Warady BA.

Semin Nephrol. 2011 Mar;31(2):213-24. doi: 10.1016/j.semnephrol.2011.01.009. Review.

PMID:
21439434
32.

Ironing out the phosphorus problem.

Zaritsky JJ, Salusky IB.

Kidney Int. 2010 May;77(10):845-7. doi: 10.1038/ki.2009.560. Review.

33.

Reduction of serum hepcidin by hemodialysis in pediatric and adult patients.

Zaritsky J, Young B, Gales B, Wang HJ, Rastogi A, Westerman M, Nemeth E, Ganz T, Salusky IB.

Clin J Am Soc Nephrol. 2010 Jun;5(6):1010-4. doi: 10.2215/CJN.08161109. Epub 2010 Mar 18.

34.

Successful treatment of calcific uremic arteriolopathy in a pediatric dialysis patient.

Amin N, Gonzalez E, Lieber M, Salusky IB, Zaritsky JJ.

Pediatr Nephrol. 2010 Feb;25(2):357-62. doi: 10.1007/s00467-009-1313-8. Epub 2009 Nov 3.

PMID:
19885686
35.

Sevelamer carbonate increases serum bicarbonate in pediatric dialysis patients.

Gonzalez E, Schomberg J, Amin N, Salusky IB, Zaritsky J.

Pediatr Nephrol. 2010 Feb;25(2):373-5. doi: 10.1007/s00467-009-1328-1. Epub 2009 Oct 30.

PMID:
19876653
36.

The utility of multivariate analysis in the study of hepcidin.

Zaritsky JJ, Young BY.

Kidney Int. 2009 Oct;76(8):912; author reply 912-3. doi: 10.1038/ki.2009.272. No abstract available.

37.

Hepcidin for clinicians.

Young B, Zaritsky J.

Clin J Am Soc Nephrol. 2009 Aug;4(8):1384-7. doi: 10.2215/CJN.02190309. Epub 2009 Jun 25. Review.

38.

Hepcidin--a potential novel biomarker for iron status in chronic kidney disease.

Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, Ganz T, Rivera S, Nissenson AR, Salusky IB.

Clin J Am Soc Nephrol. 2009 Jun;4(6):1051-6. doi: 10.2215/CJN.05931108. Epub 2009 Apr 30.

39.

Vascular access complications in long-term pediatric hemodialysis patients.

Zaritsky JJ, Salusky IB, Gales B, Ramos G, Atkinson J, Allsteadt A, Brandt ML, Goldstein SL.

Pediatr Nephrol. 2008 Nov;23(11):2061-5. doi: 10.1007/s00467-008-0956-1. Epub 2008 Aug 19.

PMID:
18712416
40.
41.

Targeted disruption of Kir2.1 and Kir2.2 genes reveals the essential role of the inwardly rectifying K(+) current in K(+)-mediated vasodilation.

Zaritsky JJ, Eckman DM, Wellman GC, Nelson MT, Schwarz TL.

Circ Res. 2000 Jul 21;87(2):160-6.

PMID:
10904001
42.

A delayed rectifier current is modulated by the circadian pacemaker in Bulla.

Michel S, Manivannan K, Zaritsky JJ, Block GD.

J Biol Rhythms. 1999 Apr;14(2):141-50.

PMID:
10194651
43.

Circadian rhythm in membrane conductance expressed in isolated neurons.

Michel S, Geusz ME, Zaritsky JJ, Block GD.

Science. 1993 Jan 8;259(5092):239-41.

PMID:
8421785

Supplemental Content

Loading ...
Support Center